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We would like to thank Dr. Aalbers and Dr. van der Woude for
their interest in our paper entitled ‘Effects of long-acting
bronchodilators and placebo on histamine-induced asthma
symptoms and mild bronchusobstruction’. The purpose of
our study consisted of comparing the effects of long-acting
bronchodilators and placebo on subjective symptom and
pulmonary function recovery. We found a similar asthma
symptom recovery 5 and 20min after inhaling salmeterol,
formoterol or placebo, despite a better recovery of the
pulmonary function in the active drug conditions. No
significant difference in the speed of recovery was found
between the formoterol and salmeterol conditions.1
The concerns raised by Aalbers and van der Woude are
principally related to the methodology of the study, more
exactly the use of a parallel-group design, the study power,
the use of a histamine provocation as an elicitor of
bronchusobstruction, and the timing of the measure
moments. Their main concerns are inspired by the absence
of difference in onset of action found between formoterol
and salmeterol, which indeed opposes current evidence in
this area.
Before taking this opportunity to discuss the methodolo-
gical concerns that have been raised, we would like to focus
on the main study purpose and on the symptom recovery
part of the manuscript. Previous research has shown
discrepancies between pulmonary function and symptoms
in asthma patients, which obviously forms an important
source of asthma management difficulties. On top of this, it
has been shown that asthma symptoms should be considered
as being multidimensional and variable across and within
individuals and situations. In this perspective, we are
convinced of the importance of in-depth symptom measure-
ments in every study design, and of questionnaires consist-
ing of multiple scales such as the Asthma Symptom Checklist
(ASC). Our findings do point out that particular attention is
needed for the patients’ subjective symptom reporting
when addressing the effects of medication as there is not
always a close correlation.
The methodological concerns raised are to our opinion
related to the belief that more distinct (significant?) effects
(and maybe a faster onset of action of formoterol compared
to salmeterol) might have been obtained if a number of
study design aspects had been different. First, Aalbers and
van der Woude question whether a crossover design may
have been more suitable for the study purpose instead of ant matter & 2006 Elsevier Ltd. All rights reserved.
2006.06.022parallel-group design, even if both designs require careful
interpretation of the results. In earlier research, it was
shown that a previous experience with a histamine
provocation can influence patients’ symptom reporting in a
later provocation, which in this case would have contami-
nated the results if a crossover design had been used.2 The
difference in baseline Borg Dyspnea Scale found in the three
groups was taken into account by including covariates and
difference scores in the statistical analyses. We share
Aalbers and van der Woude’s concerns regarding the number
of subjects included and partly in relation to this the power
of the study. The number of subjects was limited indeed, but
comparable to other studies of this nature.
In our study, results tended to show a faster pulmonary
function recovery in the formoterol than in the salmeterol
condition, but this was not significant. A fall of X20%
predicted normal FEV1 was elicited in all three conditions
before administering active drugs or placebo (mean fall of
FEV1 26.3% (standard deviation (SD) 5), 25.4 (SD 5) and 26.1
(SD 4) in, respectively, the placebo, formoterol and
salmeterol condition). Differences in onset of action in
formoterol compared to salmeterol might have been
detected if a larger fall in FEV1 had been aimed for, such
as Aalbers and van der Woude suggest. As the falls of FEV1
elicited in this study were largely clinically significant, and
as a bigger fall in FEV1 would have led us to a situation which
was not representative anymore for a real life mild
asthmatic attack, we remain convinced that a larger fall
in FEV1 would have led us too far from our study objective.
We consent with Aalbers and van der Woude’s comment
related to the problematic histamine provocation character-
istics of transient bronchoconstrictor effect, which is partly
illustrated in our study by the unexpected high levels of
spontaneous recovery of the pulmonary function. This effect
should be taken into account when interpreting the results,
and by no means we want to conclude that strong evidence is
found opposing all current evidence regarding the onset of
action of formoterol. The study methodology could be
improved with more fine-grained measurements (more
measurements, and closer in time to the drug administration
moment, such as 1 and 3min after intake). However, the
question remains to what extent such additional measure-
ments would affect subjective symptoms.
More studies are needed to draw any firm conclusions on
the effects of long-acting bronchodilators on asthma
symptoms and their variability. Based on our results,
clinicians and researchers should pay increasing attention
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the effects of medication in asthma.
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